MelhemMSolhMD

PubMed

• Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML.
  Mark J Levis, Mehdi Hamadani, Brent R Logan, Richard J Jones, Anurag K Singh
  Blood. 2025-01-07
• Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703.
  Shernan G Holtan, Javier Bolaños-Meade, Monzr M Al Malki, Juan Wu, Carrie L Kitko
  Journal of Clinical Oncology. 2025-01-03
• 1 citations
  Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy.
  Santiago Mercadal, Kwang Woo Ahn, Mariam Allbee-Johnson, Siddhartha Ganguly, Praveen Ramakrishnan Geethakumari
  Haematologica. 2025-01-01

Abstracts/Posters

• Real World Outcomes of Letermovir Prophylaxis in Unselected High Risk CMV Seropositive Hematopoietic Stem Cell Transplant Recipients
  Melhem Solh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Improved Survival in Patients Who Undergo Relapse of Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation
  Melhem Solh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refra...
  Melhem Solh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
  Melhem Solh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Reduced Toxicity Conditioning for Non-Malignant Hematopoietic Cell Transplants
  Melhem Solh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Ixazomib Maintenance to Prevent Alloreactivity and Provide Anti-Malignancy Effects Following Nonmyeloablative T-Replete Haploidentical Peripheral Blood Stem Cell Trans...
  Melhem Solh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Ver...
  Melhem Solh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Graft Versus Host Disease (GVHD) after HLA-Mismatched Haploidentical Transplantation with Post-Transplant Cyclophosphamide Compared to Matched Unrelated Donor: Inciden... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Psychological and Social Factors Are a Strong Predictor of Survival after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Independent of Disease Risk and Mor... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• A Phase II Trial of Melphalan Based Reduced Intensity Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients with Hemato... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• The Choice of Induction Regimen Affects Post Remission Survival of Acute Myelogenous Leukemia (AML) Patients with Intermediate or Poor Risk Disease 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all